FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283792334> ?p ?o ?g. }

• W4283792334 endingPage "106343" @default.
• W4283792334 startingPage "106343" @default.
• W4283792334 abstract "Although the blockade of immune checkpoint PD-1/PD-L1 has achieved great success, the lack of tumor-infiltrating immune cells and PD-L1 expression in the tumor microenvironment results in a limited response in certain tumor types. Thus, rational and optimal combination strategies were urgently needed. The combination of PD-1/PD-L1 blockade and anti-angiogenic therapy has been reported to have great potential. Here, a chimeric peptide OGS was designed by conjugating the peptides OPBP-1 (8−12) and DA7R targeting PD-L1 and VEGFR2, respectively. OGS could bind to both human and mouse PD-L1 with high affinity and block the PD-1/PD-L1 interaction, and also inhibit the migration and tube formation of HUVEC cells in wound healing and tube formation assays. To further prolong the half-life of OGS, it was modified by coupling with peptide DSP which has a high binding affinity to both human serum albumin (HSA) and mouse serum albumin (MSA) to form the peptide DSPOGS. DSPOGS could not directly affect the viability, apoptosis, and cell cycle of tumor cells in vitro, while significantly inhibiting the tumor growth in the MC38 mouse model. DSPOGS could elicit a potent anti-tumor immune response and inhibit tumor angiogenesis, with the enhancement of tumor infiltrating CD8+ T cells and the IFN-γ secreting CD8+ T cells in the spleen and tumor-draining lymph node. Further, the combination of radiotherapy with DSPOGS could dramatically improve the therapeutic efficacy. Our study could provide a promising paradigm for the combination of immune checkpoint blockade, anti-angiogenesis, and radiotherapy." @default.
• W4283792334 created "2022-07-05" @default.
• W4283792334 creator A5002981442 @default.
• W4283792334 creator A5008920774 @default.
• W4283792334 creator A5019291821 @default.
• W4283792334 creator A5024747900 @default.
• W4283792334 creator A5029017507 @default.
• W4283792334 creator A5046136378 @default.
• W4283792334 creator A5066707494 @default.
• W4283792334 creator A5086140444 @default.
• W4283792334 date "2022-08-01" @default.
• W4283792334 modified "2023-10-18" @default.
• W4283792334 title "A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy" @default.
• W4283792334 cites W1266652907 @default.
• W4283792334 cites W1999020268 @default.
• W4283792334 cites W2017560551 @default.
• W4283792334 cites W2043106306 @default.
• W4283792334 cites W2049185799 @default.
• W4283792334 cites W2052727153 @default.
• W4283792334 cites W2060846993 @default.
• W4283792334 cites W2083297935 @default.
• W4283792334 cites W2104300873 @default.
• W4283792334 cites W2109092551 @default.
• W4283792334 cites W2109598625 @default.
• W4283792334 cites W2124427232 @default.
• W4283792334 cites W2130477131 @default.
• W4283792334 cites W2137145251 @default.
• W4283792334 cites W2140872199 @default.
• W4283792334 cites W2147684729 @default.
• W4283792334 cites W2159094759 @default.
• W4283792334 cites W2165838507 @default.
• W4283792334 cites W2289794410 @default.
• W4283792334 cites W2399459450 @default.
• W4283792334 cites W2488061344 @default.
• W4283792334 cites W2527008427 @default.
• W4283792334 cites W2528386527 @default.
• W4283792334 cites W2552756732 @default.
• W4283792334 cites W2605792367 @default.
• W4283792334 cites W2728245744 @default.
• W4283792334 cites W2768158636 @default.
• W4283792334 cites W2769370325 @default.
• W4283792334 cites W2776144880 @default.
• W4283792334 cites W2786753426 @default.
• W4283792334 cites W2791474836 @default.
• W4283792334 cites W2800477374 @default.
• W4283792334 cites W2883398259 @default.
• W4283792334 cites W2896129123 @default.
• W4283792334 cites W2896980868 @default.
• W4283792334 cites W2898690691 @default.
• W4283792334 cites W2902184592 @default.
• W4283792334 cites W2903067379 @default.
• W4283792334 cites W2924479779 @default.
• W4283792334 cites W2950215033 @default.
• W4283792334 cites W2971235103 @default.
• W4283792334 cites W2983881420 @default.
• W4283792334 cites W2985933313 @default.
• W4283792334 cites W2999198943 @default.
• W4283792334 cites W3011225975 @default.
• W4283792334 cites W3022163387 @default.
• W4283792334 cites W3046643264 @default.
• W4283792334 cites W3047463220 @default.
• W4283792334 cites W3089941770 @default.
• W4283792334 cites W3106005610 @default.
• W4283792334 cites W3119365216 @default.
• W4283792334 cites W3158884963 @default.
• W4283792334 cites W3189436433 @default.
• W4283792334 cites W3207145203 @default.
• W4283792334 cites W3211659864 @default.
• W4283792334 cites W4235973183 @default.
• W4283792334 doi "https://doi.org/10.1016/j.phrs.2022.106343" @default.
• W4283792334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35798286" @default.
• W4283792334 hasPublicationYear "2022" @default.
• W4283792334 type Work @default.
• W4283792334 citedByCount "10" @default.
• W4283792334 countsByYear W42837923342022 @default.
• W4283792334 countsByYear W42837923342023 @default.
• W4283792334 crossrefType "journal-article" @default.
• W4283792334 hasAuthorship W4283792334A5002981442 @default.
• W4283792334 hasAuthorship W4283792334A5008920774 @default.
• W4283792334 hasAuthorship W4283792334A5019291821 @default.
• W4283792334 hasAuthorship W4283792334A5024747900 @default.
• W4283792334 hasAuthorship W4283792334A5029017507 @default.
• W4283792334 hasAuthorship W4283792334A5046136378 @default.
• W4283792334 hasAuthorship W4283792334A5066707494 @default.
• W4283792334 hasAuthorship W4283792334A5086140444 @default.
• W4283792334 hasConcept C121608353 @default.
• W4283792334 hasConcept C126322002 @default.
• W4283792334 hasConcept C167672396 @default.
• W4283792334 hasConcept C185592680 @default.
• W4283792334 hasConcept C203014093 @default.
• W4283792334 hasConcept C2776090121 @default.
• W4283792334 hasConcept C2776107976 @default.
• W4283792334 hasConcept C2777701055 @default.
• W4283792334 hasConcept C2780394083 @default.
• W4283792334 hasConcept C2780674031 @default.
• W4283792334 hasConcept C2780851360 @default.
• W4283792334 hasConcept C502942594 @default.
• W4283792334 hasConcept C71924100 @default.

• next